Drug intelligence / Profile preview

m118

Development stage: Phase 2
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

M118 is a novel low-molecular-weight heparin (LMWH) rationally engineered specifically for use in acute coronary syndromes (ACS). It features broad anticoagulant activity with potent action against both factor Xa (~240 IU/mg) and thrombin (factor IIa; ~170 IU/mg), low polydispersity, high subcutaneous bioavailability (78% in rabbits), and predictable pharmacokinetics. Unlike conventional LMWHs, M118's anticoagulant activity can be monitored by standard coagulation assays and is reversible with protamine, making it suitable for both surgical interventions and medical management of ACS patients.

Other names: adomiparin sodiumM118M-118M 118

Targets

F2 (Thrombin)ATIII (Antithrombin III)F10 (Factor Xa)

Beyond the preview

Go deeper on m118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on m118.

Explore the full profile